ApoC3 Attenuates Platelet Activation Through GPIIb/IIIa Receptor Interaction

Area of Science:

• Biochemistry
• Hematology
• Cardiovascular Research

Background:

• Apolipoprotein C3 (apoC3) is crucial for triglyceride metabolism and cardiovascular disease risk.
• The full physiological functions of apoC3, beyond lipid metabolism, remain largely unexplored.
• Understanding apoC3's role in hemostasis is vital for developing new therapeutic strategies.

Purpose of the Study:

• To investigate the role of apolipoprotein C3 (apoC3) in platelet function.
• To determine the impact of apoC3 on thrombus formation and platelet activation.
• To elucidate the mechanisms underlying apoC3's interaction with platelets.

Main Methods:

• Assessing apoC3's effect on platelet activation induced by ADP and collagen.
• Measuring platelet aggregation in serum with and without apoC3.
• Quantifying apoC3 binding to platelets and its effect on GPIIb/IIIa activation and P-selectin expression.

Main Results:

• Human apoC3 rapidly inhibited platelet activation at concentrations from 0.1-10 µg/mL.
• Platelet aggregation increased by over 25% when endogenous apoC3 was depleted from serum.
• ApoC3 binding to platelets reduced GPIIb/IIIa activation and P-selectin expression, with binding enhanced by ADP stimulation via GPIIb/IIIa.

Conclusions:

• Apolipoprotein C3 plays a novel inhibitory role in platelet function and thrombus formation.
• ApoC3 exhibits an endogenous regulatory function in platelet aggregation.
• These findings highlight a new link between apoC3 and vascular homeostasis, with implications for thrombotic risk.